Please login to the form below
EC
This page shows the latest EC news and features for those working in and with pharma, biotech and healthcare.
Novartis’ MS therapy Mayzent approved by NICE
Mayzent then received approval from the European Commission (EC) earlier this year, again for the treatment of adults with active SPMS.
Latest news
-
EU announces agreement with Gilead for remdesivir supply
The European Commission (EC) has signed a joint procurement agreement (JPA) with the European Commission for Gilead’s COVID-19 antiviral treatment remdesivir. ... Gilead's drug – sold under the Veklury brand name – was granted conditional approval
-
J&J signs deal with EU for 200 million COVID-19 vaccine doses
Johnson &Johnson (J&J) has signed an advance purchase agreement with the European Commission (EC) for 200 million doses of its COVID-19 vaccine following regulatory approval. ... The contract was agreed following the conclusion of exploratory discussions
-
EU will shoulder certain liability costs in AZ COVID-19 vaccine deal
Although the European Commission (EC) declined to comment on the specifics of the deal, one EU official involved in talks said that the deal was made possible thanks to the low ... The deal is to be financed with the EC’s ‘Emergency Support
-
Gavi says 76 wealthy countries have committed to COVAX vaccine facility
In contrast, the European Commission (EC) announced that it will contribute 400m to the COVAX facility, and also confirmed its interest in participating in the initiative. ... Under the Coronavirus Global Response and the Global Goal Unite campaign, we
-
EU to contribute €400m to WHO’s COVID-19 vaccine facility
Under the Coronavirus Global Response and the Global Goal Unite campaign, we have seen the world come together as one,” said Ursula von der Leyen, president of the EC. ... that we can build back up better and healthier,” said Jutta Urpilainen,
More from news
Approximately 15 fully matching, plus 277 partially matching documents found.
Latest Intelligence
-
Strengthening business competition and reducing anti-competitive practices
This appears to be a global trend, not least (from a European perspective) since the European Commission (EC) published its final report in its pharmaceutical sector inquiry in July 2009. ... Settling the score. While the level of financial penalties
-
A new EU in the making, what lies ahead for pharma?
Margrethe Vestager was being tipped as a possible EC President. She has taken a very tough line on competition and IP, which are obviously big issues for pharma, and has taken
-
Tackling a formidable foe
A year ago the company won EC approval for MAVENCLAD, a course of just 20 tablets that tames the body’s immune response system and can be taken on ten consecutive
-
The sound of silence puts the squeeze on generics and biosimilars
EFPIA issued a statement on its position, stating: “The SPC regime is part of the current EC review of incentives.
-
European CTR implementation advances ethical assessment of clinical trials
well as a clear process of selection of a Central ‘EC’ that will be dealing with a trial. ... who would deal with a selection of the appropriate EC, timelines and financial aspects.
More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.
Latest appointments
-
CureVac’s CEO appointed to EC High Level Group
Dr Hoerr joins a panel of 15 group members who will advise the EC on how to strengthen support for breakthrough, market-creating innovation in the Horizon 2020 project as well
-
New EC health director general takes office
Prats Monné's appointment was part of a reshuffle of the Commission's senior management by president Jean-Claude Juncker and, in a statement, the EC said the changes were a
-
IMI appoints new chair of scientific committee
Portugal’s Maria Beatriz da Silva Lima to join EC’s collaborative research group. ... the EC and the industry to improve health innovation in Europe.
-
Jonathan Dickinson joins Ariad from BMS
He joins at an important time for Ariad in Europe as it prepares to launch its chronic myeloid leukaemia treatment Iclusig (ponatinib), pending approval from the European Commission (EC).
-
Tonio Borg nominated to replace John Dalli as EC Health Commissioner
Candidacy of the Maltese deputy prime minister and minister of foreign affairs accepted by Barroso
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Will COVID-19 necessitate a change in thinking around clinical trials?
The challenge with any clinical study is that every site visit is dictated by the protocol, which has been EC/IRB approved. ... will need to be reported for EC/IRB approvals.
-
Fake News is Bad for your Health
Viral misinformation. Nature, 16 October 2018. http://www.nature.com/articles/d41586-018-07034-4?
-
Rare Disease Day 2019: A patient perspective on primary sclerosing cholangitis
Goode EC, Clark AB, Mells GM et al. Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system.
-
Ensuring quality in medical translation when working ‘blind’
There is also often the need for a review by an Ethics Committee (EC), which can remove some errors, but can introduce spelling or grammar errors too. ... Any EC or client changes should be sent back to the original translators to be checked again.
-
Can rare diseases be a viable option for the pharma industry?
EU has enacted similar legislation, Regulation (EC) No 141/2000, in which pharmaceuticals developed to treat rare diseases are referred to as “orphan medicinal products”.
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- FDA sets November date for expert panel review of Biogen’s aducanumab
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b
- Vaccine developers call on FDA to offer clarity on COVID-19 trials
- How will the events and exhibitions industry change post-Coronavirus?
- Novartis weathers the COVID-19 storm in Q3, lifts outlook
- Eli Lilly ends COVID-19 antibody trial in hospitalised setting, other studies continue
- Researchers say COVID-19 antibody levels have fallen rapidly in the UK
- Exploring the potential of eosinophils
- Eliminating pharmaceutical rebates, is this déjà vu?
- Bayer pays an initial $2bn for gene therapy firm AskBio
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...
Latest intelligence
- Exploring the potential of eosinophils
- GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
- Eliminating pharmaceutical rebates, is this déjà vu?
- By Andrew Parece and Matthew Majewski...
- Patients are ready to embrace decentralised clinical trials, are you?
- Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Quick links
Infographics
